您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CPI-455
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CPI-455
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CPI-455图片
包装与价格:
包装价格(元)
5mg电议
25mg电议
500mg电议
1g电议

产品介绍
CPI-455 是一种特异性的泛 KDM5 抑制剂,对 KDM5A 的 IC50 为 10 nM。 CPI-455 介导 KDM5 抑制,提高 H3K4me3 的整体水平,并减少用标准化疗或靶向药物治疗的多个癌细胞系模型中耐药性持续癌细胞的数量。

Cell experiment:

MCF-7 is a luminal breast cancer cell line. MCF-7 is grown in MEM supplemented with 10% fetal bovine serum (FBS) and is incubated at 37℃ with a 5% CO2 atmosphere. For each treatment condition, 2.5×105 MCF-7 cells are plated in T25 flask and allowed to rest overnight. The following day, the media is aspirated and replaced with media containing DAC at a final concentration of 62.5 nM. DAC media is aspirated and replaced every 24 hours for a total treatment time of 72 hours. Following DAC treatment, media is aspirated and replaced with media supplemented with 2% FBS containing KDM5 inhibitors (e.g., CPI-455) at a final concentration of 9.375 μM. Cells are harvested following 72 hours of KDM5 inhibitor treatment[1].

文献引用
产品描述

IC50: 10 nM

CPI-455 is a KDM5 inhibitor.

The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs).

In vitro: Previous study found that CPI-455 could potently inhibit the fulllength KDM5A in enzymatic assays with a half-maximal inhibitory concentration of 10 ± 1 nM. CPI-455 inhibited KDM5A, KDM5B and KDM5C to similar levels but showed significantly weaker potency toward KDM4C and KDM7B (~200- and 770-fold, respectively) and no detectable inhibition of KDM2B, KDM3B or KDM6A. Moreover, it was found that the CPI-455-mediated KDM5 inhibition led to a dose-dependent increase in global H3K4me3 in HeLa cells, and the removal of CPI-455 resulted in a rapid reversal of H3K4me3 increases in HeLa cells. Moreover, CPI-455 could delay the appearance of heavy H3K4me3, which was consistent with the role for KDM5 enzymes in H3K4me3 turnover, however, the turnover of H3K4me2 was only marginally altered. As expected, CPI-455 could affect the turnover of H3K4 monomethylation [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, CPI-455 is still in the preclinical development stage.

Reference:
[1] Vinogradova M, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016 Jul;12(7):531-8.